Autor: |
Ondoa, Pascale, Ndlovu, Nqobile, Keita, Mah-Sere, Massinga-Loembe, Marguerite, Kebede, Yenew, Odhiambo, Collins, Mekonen, Teferi, Ashenafi, Aytenew, Kebede, Amha, Nkengasong, John |
Předmět: |
|
Zdroj: |
African Journal of Laboratory Medicine; 2020, Vol. 9 Issue 2, p1-10, 10p |
Abstrakt: |
Access to diagnostics remains sub-optimal in Africa due to limited human, financial and technical resources that affect various components of the health system.[1],[2] Additionally, the lack of standardised systems for evaluation and registration of diagnostics[3] cripples the introduction of better technologies, representing missed opportunities to address healthcare challenges. In addition to 70% of patients not being notified, a rifampicin susceptibility test was available to less than 10% of patients in 23 of 47 countries and second-line resistance testing was available only in 60% of the countries on the continent.[7] The picture is equally worrisome for diseases that are poorly or not supported through dedicated programmes. Assisting countries to define tier-specific testing packages that address the needs of clinical diagnostics and disease surveillance is another important intervention with the potential to guide the introduction of diagnostics at the levels where they are most needed and cost-effective. [Extracted from the article] |
Databáze: |
Supplemental Index |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|